Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Agonist

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43873   clinical trials with a EudraCT protocol, of which   7292   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    736 result(s) found for: Agonist. Displaying page 1 of 37.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-008722-73 Sponsor Protocol Number: PPP/2008 Start Date*: 2009-04-20
    Sponsor Name:AZIENDA OSPEDALIERA PISANA
    Full Title: ROLE OF PAROXETINE AS ADD-ON THERAPY TO GNRH AGONIST IN THE TREATMENT OF ENDOMETRIOSIS-RELATED CHRONIC PELVIC PAIN
    Medical condition: Endometriosis-associated pelvic pain
    Disease: Version SOC Term Classification Code Term Level
    9.1 10014778 Endometriosis LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003645-16 Sponsor Protocol Number: 2019_0012 Start Date*: 2020-02-25
    Sponsor Name:Hopital Foch
    Full Title: Benefit of the GnRH agonist before frozen embryo transfer in patients with endometriosis and / or adenomyosis: randomized prospective study
    Medical condition: Frozen embryo transfer in patients with endometriosis and/or adenomyosis
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000585-22 Sponsor Protocol Number: FE 200486 CS27 Start Date*: 2008-06-20
    Sponsor Name:Ferring Arzneimittel GmbH
    Full Title: An Open-Label, Multi-Centre, Uncontrolled, Exploratory Study, Investigating Degarelix One-Month Dosing Regimen as Second-Line Hormonal Treatment after PSA-Failure in GnRH Agonist Treated Patients w...
    Medical condition: Prostate Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002010-38 Sponsor Protocol Number: SC3-90049-001 Start Date*: 2005-11-21
    Sponsor Name:Institut de Recherches Internationales Servier (I.R.I.S.)
    Full Title: Assessment of the acceptability of a sublingual formulation of piribedil (S90049), 10 to 30 mg on request (maximum 5 times a day) on the top of L-dopa and a dopamine agonist in advanced Parkinson D...
    Medical condition: Advanced Parkinson´s Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000821-30 Sponsor Protocol Number: SAD13-ER1 Start Date*: 2013-07-12
    Sponsor Name:Enrique Rey Díaz-Rubio
    Full Title: CLINICAL RESPONSE TO 5HT4 RECEPTORS AGONIST (PRUCALOPRIDE): GASTROCOLIC REFLEX
    Medical condition: chronic constipation
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001403-33 Sponsor Protocol Number: TCTLR-101 Start Date*: 2023-06-06
    Sponsor Name:Ascendis Pharma Oncology Division A/S
    Full Title: Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumor...
    Medical condition: Locally advanced or metastatic solid tumor malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10049280 Solid tumour LLT
    21.1 100000004864 10065143 Malignant solid tumour LLT
    21.1 100000004864 10065147 Malignant solid tumor LLT
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) HU (Prematurely Ended) NL (Ongoing) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-004460-31 Sponsor Protocol Number: PRINT Start Date*: 2007-02-21
    Sponsor Name:Guy's & St Thomas' NHS Foundation Trust
    Full Title: A randomised controlled trial comparing the gonadotrophin releasing hormone (GnRH) agonist long regimen versus the GnRH agonist short regimen versus the GnRH antagonist regimen in poor responders u...
    Medical condition: Poor ovarian response in women undergoing In vitro Fertilisation (IVF) treatment.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10056204 In vitro fertilisation PT
    Population Age: Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-000794-31 Sponsor Protocol Number: October2011,version5 Start Date*: 2011-06-15
    Sponsor Name:Dept. of Pharmacology
    Full Title: Neurodegenerative Changes in Alzheimer’s Disease: Identifying potential effects of Victoza® on degenerative changes
    Medical condition: Alzheimer's disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004213-16 Sponsor Protocol Number: A-97-52014-181 Start Date*: 2012-05-01
    Sponsor Name:Ipsen Ltd
    Full Title: A PHASE IV, RANDOMISED, OPEN-LABEL, MULTI-CENTRE STUDY TO ASSESS THE IMPACT ON DISEASE CONTROL, SAFETY, PATIENT AND CLINICIAN EXPERIENCE OF CHANGING PATIENTS WITH ADVANCED PROSTATE CANCER FROM A 3-...
    Medical condition: locally advanced and metastatic prostrate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: Removed from public view
    EudraCT Number: 2007-004096-19 Sponsor Protocol Number: BALTI Prev 2007 Start Date*: 2007-10-31
    Sponsor Name:Birmingham Heartlands Hospital
    Full Title: Beta Agonist Lung injury Trial - Prevention Study
    Medical condition: This programme of research will examine the role of beta-2 agonist as specific pharmacotherapy to reduce the incidence of Acute Lung Injury (ALI) / Acute Respiratory Distress Syndrome (ARDS) in pat...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-003001-94 Sponsor Protocol Number: MSGLP Start Date*: 2019-11-06
    Sponsor Name:Lekárska fakulta UK Bratislava
    Full Title: Use of GLP-1 analogs in the treatment of multiple sclerosis
    Medical condition: Our hypothesis is that patients with MS have a disorder of energy metabolism in neurons and glial cells of the CNS, contributing to the development and progression of demyelinating foci and neurode...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004709-53 Sponsor Protocol Number: 911 Start Date*: 2005-12-05
    Sponsor Name:Merck Sharp & Dohme OÜ
    Full Title: A Multicenter, Double-Blind, Randomized, Cross-Over Design Study to Evaluate the Effect of Montelukast vs. Salmeterol on the Inhibition of Excercise-Induced Bronchoconstriction in Asthmatic Patient...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    8.0 10003553 LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: EE (Completed) ES (Completed) IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-021403-24 Sponsor Protocol Number: 001 Start Date*: 2010-11-10
    Sponsor Name:North Lincolnshire and Goole NHS Foundation Trust
    Full Title: A Prospective Pilot Study to Investigate the Effectiveness of Quinagolide in the Improvement of Psychological Symptoms Associated with Hyperprolactinaemia.
    Medical condition: Hyperprolactinaemia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10020737 Hyperprolactinaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-005631-29 Sponsor Protocol Number: 24420221 Start Date*: 2008-06-18
    Sponsor Name:Center for Spiseforstyrrelse, Endokrinologisk Afdeling M, Odense Universitetshospital
    Full Title: Cannabinoid CB1 receptor agonist treatment in severe chronic anorexia nervosa
    Medical condition: severe chronic Anorexia Nervosa
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002649 Anorexia nervosa PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-003986-11 Sponsor Protocol Number: 1401-MAD-004-IO Start Date*: 2016-10-22
    Sponsor Name:IVI Madrid
    Full Title: Prospective, double-blinded, randomized clinical trial to evaluate the potential benefitial effect of resveratrol for preventing the ovarian hyperstimulation syndrome.
    Medical condition: Resveratrol may prevent the incidence of ovarian hyperstimulation syndrome by reducing the expression of VEGF and estradiol, improving the haemoconcentration and ascitis Re
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-003861-34 Sponsor Protocol Number: 0/2004 Start Date*: 2005-06-08
    Sponsor Name:Department of Nuclear Medicine
    Full Title: Influence of the PPAR gamma -agonist Pioglitazone on endothelial function in the peripheral and myocardial vascular territories and on myocardial efficiency in obese subjects
    Medical condition: There is an association between insulin resistance and endothelial dysfunction which is thought to be a critical factor in the development of vascular disease and thus an important factor in the de...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003871-19 Sponsor Protocol Number: srhths01 Start Date*: 2006-09-19
    Sponsor Name:Salford Royal Hospital
    Full Title: A randomised control trial to identify the effects of cinacalcet on bone and cardiovascular health in end-stage renal disease
    Medical condition: Secondary hyperparathyroidism in renal failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-004245-16 Sponsor Protocol Number: NL67646.068.18 Start Date*: 2019-04-16
    Sponsor Name:Maastricht University
    Full Title: Targeting the beta-2 adrenergic pathway to improve skeletal muscle glucose uptake in healthy humans
    Medical condition: Type 2 diabetes
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-000731-31 Sponsor Protocol Number: NL76746.068.21 Start Date*: 2021-10-14
    Sponsor Name:Maastricht University
    Full Title: Targeting the beta-2 adrenergic pathway to improve skeletal muscle glucose uptake in obese humans
    Medical condition: Type 2 diabetes mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001191-34 Sponsor Protocol Number: ASND0029 Start Date*: 2023-07-13
    Sponsor Name:Ascendis Pharma Oncology Division A/S
    Full Title: IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination with Pembrolizumab, Standard of...
    Medical condition: locally advanced or metastatic solid tumor malignancies, platinum resistant ovarian cancer, post-anti-pd-1 melanoma, second line or later cervical cancer, neoadjuvant melanoma and neoadjuvant non-s...
    Disease: Version SOC Term Classification Code Term Level
    24.1 10022891 - Investigations 10085681 Carbohydrate antigen 242 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 06 17:01:13 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA